Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sandra M Swain

Showing results (91-100 of 210) with videos related to

Pageof 21
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 25, 2024
Clinical Study Report and Individual Participant Data Transparency for US Food and Drug Administration-Approved Anticancer Drugs: A Call for Systematic Data AvailabilityNatansh D Modi, Sandra M Swain, Marc Buyse, et al.
Clinical Breast Cancer|June 15, 2012
Evaluation of lymphangiogenic factors, vascular endothelial growth factor D and E-cadherin in distinguishing inflammatory from locally advanced breast cancerPaul H Levine, Chia C Portera, Heather J Hoffman, et al.
Journal of Oncology Practice|February 19, 2015
Improving Documentation of Pain Management at MedStar Washington Cancer InstituteVishal Ranpura, Sundeep Agrawal, Puja Chokshi, et al.
Breast Cancer Research and Treatment|February 28, 2008
Amenorrhea in premenopausal women on the doxorubicin-and-cyclophosphamide-followed-by-docetaxel arm of NSABP B-30 trialSandra M Swain, Stephanie R Land, Marcie W Ritter, et al.
The Journal of Clinical Investigation|January 4, 2003
Rapid Akt activation by nicotine and a tobacco carcinogen modulates the phenotype of normal human airway epithelial cellsKip A West, John Brognard, Amy S Clark, et al.
The Oncologist|March 12, 2013
Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III studySandra M Swain, Michael S Ewer, Javier Cortés, et al.
Journal of Translational Medicine|November 28, 2021
The tumor immune microenvironment of primary and metastatic HER2- positive breast cancers utilizing gene expression and spatial proteomic profilingIlana Schlam, Sarah E Church, Tyler D Hether, et al.
Breast Cancer Research and Treatment|December 17, 2009
Gene expression pathway analysis to predict response to neoadjuvant docetaxel and capecitabine for breast cancerLarissa A Korde, Lara Lusa, Lisa McShane, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 19, 2010
Akt phosphorylation at Ser473 predicts benefit of paclitaxel chemotherapy in node-positive breast cancerSherry X Yang, Joseph P Costantino, Chungyeul Kim, et al.
The Lancet. Oncology|December 15, 2016
Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA studyStephen J Luen, Roberto Salgado, Stephen Fox, et al.
Pageof 21

Showing results (91-100 of 210) with videos related to

Sort By:
Pageof 21
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 25, 2024
Clinical Study Report and Individual Participant Data Transparency for US Food and Drug Administration-Approved Anticancer Drugs: A Call for Systematic Data AvailabilityNatansh D Modi, Sandra M Swain, Marc Buyse, et al.
Clinical Breast Cancer|June 15, 2012
Evaluation of lymphangiogenic factors, vascular endothelial growth factor D and E-cadherin in distinguishing inflammatory from locally advanced breast cancerPaul H Levine, Chia C Portera, Heather J Hoffman, et al.
Journal of Oncology Practice|February 19, 2015
Improving Documentation of Pain Management at MedStar Washington Cancer InstituteVishal Ranpura, Sundeep Agrawal, Puja Chokshi, et al.
Breast Cancer Research and Treatment|February 28, 2008
Amenorrhea in premenopausal women on the doxorubicin-and-cyclophosphamide-followed-by-docetaxel arm of NSABP B-30 trialSandra M Swain, Stephanie R Land, Marcie W Ritter, et al.
The Journal of Clinical Investigation|January 4, 2003
Rapid Akt activation by nicotine and a tobacco carcinogen modulates the phenotype of normal human airway epithelial cellsKip A West, John Brognard, Amy S Clark, et al.
The Oncologist|March 12, 2013
Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III studySandra M Swain, Michael S Ewer, Javier Cortés, et al.
Journal of Translational Medicine|November 28, 2021
The tumor immune microenvironment of primary and metastatic HER2- positive breast cancers utilizing gene expression and spatial proteomic profilingIlana Schlam, Sarah E Church, Tyler D Hether, et al.
Breast Cancer Research and Treatment|December 17, 2009
Gene expression pathway analysis to predict response to neoadjuvant docetaxel and capecitabine for breast cancerLarissa A Korde, Lara Lusa, Lisa McShane, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 19, 2010
Akt phosphorylation at Ser473 predicts benefit of paclitaxel chemotherapy in node-positive breast cancerSherry X Yang, Joseph P Costantino, Chungyeul Kim, et al.
The Lancet. Oncology|December 15, 2016
Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA studyStephen J Luen, Roberto Salgado, Stephen Fox, et al.
Pageof 21